Hemab raises USD 55m for treatment of rare bleeding disorders

In less than a year, Danish biotech company Hemab, which builds on technology developed by Novo Nordisk and Genmab, has gone from seed investments to a large capital fund raising round – and now to clinical trials.
Hemab's new CEO, Benny Sørensen | Photo: Hemab / PR
Hemab's new CEO, Benny Sørensen | Photo: Hemab / PR
BY ELIZABETH MØNSTED JOHANSEN, TRANSLATED BY CATHERINE BRETT

Things have moved quickly at Hemab since the company was founded almost two years ago – and gone even faster since the company secured an introductory seed investment from Novo Holdings in December.

Already a subscriber?Log in here

Read the whole article

Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

With your free trial you get:

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
!
!
Must contain at least 6 characters
!
Must contain at least 2 characters
!
Must contain at least 2 characters

Get full access for you and your coworkers

Start a free company trial today

Sign up for our newsletter

Stay ahead of development by receiving our newsletter on the latest sector knowledge.

!
Newsletter terms

Front page now

Further reading